Pfizerlifted the bottom end of its full-year revenue guidance on Tuesday, citing growth in its non-Covid pharmaceutical portfolio. Its smaller Covid vaccine partner offered a less optimistic outlook.… [+99 chars]
No comments yet. Be the first to comment!